MED19 is a member of the
INTRODUCTION
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in the Western male population (1) . It is estimated that approximately 27,000 victims die of prostate cancer each year, although advances in early detection and treatment have reduced mortality these years (2) . Moreover, there is a significant number of men who require systemic therapy and ongoing surveillance for advanced prostate cancer (3) . Therefore, novel approaches and agents are urgently needed for the prevention and treatment of prostate carcinoma. High throughput technologies, such as DNA and protein microarrays, have enabled the identification of genes and their corresponding proteins that are differentially regulated in malignant conditions (4) .
Mediator complex subunit 19 (MED19) is a component of the mediator complex which is a coactivator for DNA-binding factors that activate transcription via RNA polymerase II (5) . It was originally identified in a search for mutants that increased the aerobic expression of the CYC7 gene, and was initially found to be encoded by an essential gene product (6) . Gene expression microarray studies of a MED19 deletion strain and a truncation strain have shown that a diverse range of genes were both up-and down-regulated (7) . MED19 was involved in head-module subunits in mammalian mediator complex (8) . The largely intact Δmed19(rox3) complex facilitates activated transcription at levels similar to the wild type mediator; However, in the absence of the middle module, the Δmed19(rox3) mediator was defective in enhanced basal transcription, enhanced transcription factor II H (TFIIH) phosphorylation of the carboxy terminal domain (CTD), as well as binding of RNA Pol II and the CTD (9) . Recently, MED19 was identified as one of critical components of the regulatory apparatus employed by the repressor element 1 (RE1) silencing transcription factor (10). MED19 encodes lung cancer metastasis-related protein (LCMR1) in human genome (11, 12) . Its functional role in human prostate cancer is still unclear. Loss of either MED1/TRAP220 or MED17 in prostate cancer cells significantly decreased both androgen-dependent and -independent cellular proliferation, inhibited cell cycle progression, and increased apoptosis (13) . Hence, we hypothesized that MED19 was involved in the transportation of cell signals from the exterior to the interior of the nucleus, cell cycle regulation, and the regulation of transcription in carcinomas.
To explore the functional role of MED19 in prostate cancer, we performed the infection into PC-3 and DU145 cells with lentivirus expressing short harpin RNA (shRNA) against MED19, and investigated the effect of MED19 silencing on the cell proliferation, tumorigenesis cell cycle, and apoptosis.
RESULTS

Infection of lentivirus containing shRNA targeting MED19 in PC-3 cells
To assess the role of MED19 in prostate carcinoma, we synthe-http://bmbreports.org The RNAi-1 group showed significant decrease in the DNA synthesis on the second day, indicating a decreased proliferative ability (*P ＜ 0.01). (F) The effect of MED19 downregulation on cell proliferation in PC-3 cells was also repeated by using another siRNA against MED19 to get comparable results. The cell viability was significantly lower in the RNAi-1 and RNAi-2 groups than in control (*P ＜ 0.01). sized MED19 siRNA (5'-GGTGAAGGAGAAGCTAAGT-3') and packaged recombined lentivirus expressing MED19 shRNA (RNAi-1). GFP expression was observed in PC-3 cells 4 days after lentivirus infection at MOI 20 (Fig. 1A) . Quantitative real-time (Q-PCR) results showed that the expression of MED19 mRNA was decreased by 75.7% in MED19 knock-down cells, compared to the control (P ＜ 0.01; Fig. 1B) . Moreover, the expression of MED19 protein was significantly lower after 7 days of RNAi-1 in-http://bmbreports.org BMB reports fection (Fig. 1C) , demonstrating that MED19 was efficiently downregulated in PC-3 cells by lentivirus-mediated shRNA.
Suppression of MED19 inhibited the growth of PC-3 cells
After infection with RNAi-1 for 5 days, MTT and BrdU incorporation assay were used to assess the effect of MED19 silencing on cell proliferation in PC-3 cells. Compared to the control, the number of viable cells was reduced by 49.7% after 5 days of incubation in RNAi-1 group (P ＜ 0.01; Fig. 1D ), and the level of newly synthesized DNA was decreased by 76.9% on the second day (P ＜ 0.01; Fig. 1E ), which indicated a impaired proliferative ability in PC-3 cells. To rule out off-target effects caused by the siRNA, relevant data was also confirmed with an additional RNAi sequence (5'-CGAATCTGATCACACACTA-3') that deplete MED19 and inhibited cell proliferation with a similar efficiency (Fig. 1F) .
Silencing of MED19 suppresses the colony-forming capacity and tumorigenesis of PC-3 cells
Giemsa stained colonies in Fig. 2A revealed that stable infection of RNAi-1 resulted in dramatic decrease in the number and size of colonies. Compared to the control, the cell number per colony and colony count per well were reduced by 43.0% and 51.0% in RNAi-1 group, respectively (P ＜ 0.05; Fig. 2B and C). To investigate the in vivo effect of MED19 shRNA, on tumorigenesis a prostate carcinoma xenograft model was established (Fig. 2D) . Four weeks of inoculation, the average tumor volume was 2.4-fold and 1.9-fold larger in PC-3 group and control group than in RNAi-1 group (P ＜ 0.05; Fig. 2E ). Tumor xenografts were finally separated (Fig. 2F) , and a significant different in the tumor weight was observed between control and RNAi-1 groups (P ＜ 0.05; Fig. 2G ). Moreover, the expression of MED19 in tumors from RNAi-1 group was significantly lower than in control (Fig.  2H) . Our in vivo results revealed that silencing of MED19 suppressed the tumor formation and growth in prostate cancer cells.
Effect of MED19 downregulation on the growth of DU145 cells
The silencing of MED19 in another prostate cancer line, DU145 cells, was substantiated by Western blotting (Fig. 3A) . The cell proliferation was significantly inhibited after 5 days of RNAi-1 infection as evidenced by MTT assay (P ＜ 0.01; Fig. 3B ). Moreover, thecolony count was proved to be only 30.5% smaller in MED19 knock-down cells than in control (P ＜ 0.01; Fig. 3C, D) .
In conclusion, lentivirus-mediated MED19 shRNA impaired the cell proliferation and colony formation in DU145 cells.
Effect of MED19 downregulation on the cell cycle and apoptosis
Flow cytometry assay was performed to further assess the role of MED19 in the regulation of cell cycle progression and apoptosis.
Compared to the control, the proportion of S-phase cells was increased by 47.0% and 23.7% in RNAi-1 infected PC-3 cells and DU-145 cells (Fig. 4A, B ). This demonstrates that MED19 knockdown cells underwent significant S-phase arrest. Next, we wanted to determine whether MED19 was an inducer of apoptosis. The apoptosis profile was different between the control group and RNAi groups (Fig. 4C ). Cell apoptosis induced by MED19 siRNAs was significantly increased in comparison with control ( Fig. 4D) , indicating that the growth inhibition was associated http://bmbreports.org with an increase in cell apoptosis. Furthermore, apoptotic proteins such as Bid, caspase-7 and cell cycle proteins, including CDK2 and CDK4, were measured by Western blotting. We found that CDK2 and CDK4 were downregulated, while Bid and caspase-7 were upregulated significantly (Fig. 4E) .
DISCUSSION
MED19 is a member of transcription factors that regulate the gene expression and may be responsible for aberrant of cell growth and tumor formation. So far, the expression of MED19 has not been explored in prostate cancer. In our previous study, we examined the presence of MED19 protein in prostate cancer specimens by immunohistochemical assay. It was suggested that MED19 was specifically highly expressed in the prostate tumor tissues, compared to the paired non-neoplastic tissues (data not shown). Next, we constructed lentiviruses containing shRNAs targeting MED19 and infected prostate cancer cell lines. The primary goal of this research was to explore the role of MED19 in cell proliferation and tumorigenesis in prostate cancer. After silencing of MED19 by lentivirus-mediated RNAi, the proliferation of PC-3 and DU145 cells was significantly inhibited. Furthermore, infection of lentivirus containing shRNA targeting MED19 resulted in lower colony formation ability and attenuated tumor formation and growth in PC-3 xenografts. This in vivo result provided new support for the role of MED19 in promoting neoplasia, which support the results of previous studies that reported an induction of tumorigenesis in hepatocellular carcinoma and lung cancer cells treated with MED19 siRNAs (14, 15) . Together, these findings justified the potential usefulness of MED19 as a prostate cancer biomarker.
Abnormal regulation of the cell cycle is a hallmark of carcinoma genesis. In this study, it revealed that PC-3 and DU145 cells were arrested in S-phase when infected with lentiviruse containing shRNA targeting MED19, which suggested that MED19 is involved in control of post-mitotic cellular process. Various studies have shown the involvement of cell cycle regulation-mediated apoptosis as a mechanism of cell growth inhibition (16, 17) . In eukaryotes, passage through the cell cycle is governed by the function of a family of protein kinase complexes (18) . Under normal conditions, the protein kinase complexes are activated at specific intervals and through a series of events, resulting in the progression of cells through the different phases of the cell cycle, thereby ensuring normal cell growth (19) . Any defect in this machinery causes altered cell cycle regulation that may result in unwanted cellular proliferation, potentially culminating in the development of cancer. CDK2 and CDK4, subunits of the protein kinase complex, are involved in cell cycle regulation (G1 to S transition). Interestingly, our data showed that CDK2 and CDK4 was downregulated in PC-3 cells, which maybe not consistent with the S phase arrest after MED19 siRNA treatment observed by flow cytometry. Similar to our results, in a human hepatocellular carcinoma cells line, the cell cycle was also arrested in the S phase by decreasing CDK4 protein expression (20) However, further investigation is desirable to reveal the underlying mechanism by which MED19 modulates the cell cycle.
Our results also showed that knocking down MED19 caused upregulation of apoptotic caspase Caspase 7 and pro-apoptotic protein Bid, which results in enhancement of cell apoptosis. Moreover, MED19 knock-down cells may be dying a programmed cell death with undergoing an S-phase arrest.
In conclusion, downregulation of endogenous MED19 induces growth inhibition, S-phase arrest, apoptosis, and changes in cell cycle and apoptosis regulators in prostate cancer cells. MED19 acts as a carcinogene and might be useful as an adjunctive therapeutic agent for advanced prostate cancer. A better understanding of MED19 function and processing may provide novel insights into the clinical therapy of prostate cancer.
MATERIALS AND METHODS
Cell culture
Prostate cancer cell lines PC-3 and DU145 were obtained from the American Type Culture Collection (ATCC, Rockville, MD) and grown in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1 mM nonessential amino acids at 37 o C and 5% CO2.
Lentivirus-mediated RNA interference
The double-strand oligo-DNA containing the small interfering RNAs (siRNAs) against MED19 (NM_153450) or non-silencing siRNA were linked to the linear plasmid pGCL-GFP (Shanghai GeneChem, China). The production of recombinant plasmids afterwards were transfected into HEK293T cells together with helper plasmids (all obtained from Shanghai GeneChem) using Lipofectinmine 2000 (Invitrogen, Carlsbad, CA) to generate lentiviruses. After 72 h of transfection, lentiviruse particles were harvested and concentrated by ultracentrifugation. PC-3 and DU145 cells were seeded at 6-well plates (5 × 10 4 cells/ml) and infected with lentiviruses containing shRNAs targeting MED19 or control lentivirus at multiplicity of infection (MOI) of 20.
Q-PCR
After 5 days of infection, total cellular RNA was extracted with Trizol reagents (Invitrogen, Carlsbad, CA) and corresponding first-strand cDNA was synthesized using M-MLV-RTase (Promega, Madison, WI) according to the manufacturer's protocols. The amount of MED19 mRNA knock-down was quantified by employing Q-PCR using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The primer sequences for MED19 were: 5'-TGACAG-GCAGCACGAATC-3' and 5'-CAGGTCAGGCAGGAAGTTAC-3'. The primer sequences for GAPDH, an internal control, were 5'-TGACTTCAACAGCGACACCCA-3' and 5'-CACCCT-GTTGCTGTAGCCAAA-3'. Relative expression of MED19 http://bmbreports.org BMB reports mRNA was calculated using 2-ΔΔCt method (21) .
Western blot analysis
After 7 
Cell proliferation assay
Cell viability was assessed by MTT assay 5 days after lentivirus infection (22) . Briefly, cells were seeded into 96-well plates (2 × 10 4 cells/ml) and allowed to grow for 5 days, respectively. Twenty microliter (5 mg/ml) of MTT was added and incubated for 4 h. The supernatant was removed and 150 μl DMSO was added. The optical density (OD) of each well was measured at 570 nm.
The DNA synthesis ability was measured by BrdU incorporation assay (22) . Briefly, cells were seeded into 96-well plates (2 × 10 4 cells/ml) and allowed to grow for 2 days. BrdU Cell Proliferation Assay Kit (Chemicon International Inc., Temecula, CA) was used, and the OD of each well was measured at 490 nm.
Colony formation analysis
Colony formation analysis was conducted 5 days after lentivirus infection as previously described (22) . Cells were seeded into 6-well plates (300 cells/ml) and cultured normally for 14 days. Then colonies were washed with PBS twice, fixed in paraform and stained with Giemsa. The number of colonies was counted under fluorescence microscope.
Cell cycle analysis
After lentivirus infection for 5 days, cells were spread onto 60-mm tissue culture dishes and incubated to reach 80% confluence. Then, cells were fixed in 70% ice-cold ethanol and stained with propidium iodide (40 μg/ml) in RNase (100 μg/ml). Tests were performed in triplicate for each sample. Analysis of cell cycle distribution was performed on a flow cytometer (FACS Calibur, BD, Franklin, NJ) with dedicated software.
Apoptosis assay
The Annexin V-PE and 7-AAD double staining flow cytometry apoptosis detection kit (BD Biosciences, San Jose, CA) was used according to the manufacturer's suggestions. Briefly, PC-3 cells grown in 60-mm tissue culture dishes were infected with lentivirus for 7 days. Both floating and attached cells were collected in PBS and centrifuged. The supernatant was discarded and the pellets were resuspended in binding buffer at 1 × 10 6 cells/ml. After incubation with the dye for 15 min, cells were analysed on a FACSCalibur flow cytometer.
Assessment of tumor growth
Thirty male BALB/c nude mice (4-6 weeks old, 18-22 g) were purchased from Shanghai Slac Laboratory Animal Co., Ltd. and randomly divided into three groups (each containing 10 mice). The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee of the Second Military Medical University. Animals received a subcutaneous injection of 0.15 ml of parent PC-3 cells or lentivirus infected cells (5 × 10 6 cells/ml). Tumor growth was assessed on an indicated interval by measuring tumor size with digital calipers. The formula: 0.52 × a 2 × b, where a = minor diameter and b = major diameter, was used to calculate the tumor volume. Tumors were dissected and weighed 4 weeks after inoculation and subjected to Western blotting.
Statistical analysis
Data were expressed as mean ± SD and were statistically analyzed using unpaired Student's t test or ANOVA analysis with the SPSS 10.0 statistical package. P ＜ 0.05 was considered statistically significant.
